Gilead Sciences, Inc.

Stocks

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-10 EDT			5-day change	1st Jan Change
133.06 ^USD	-0.11%		+2.19%	+8.41%

08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT

Transcript : Gilead Sciences, Inc. - Special Call

Published on 04/07/2026 at 07:00 pm EDT - Modified on 04/07/2026 at 11:50 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good afternoon. Thank you for attending today's Gilead Sciences update on proposed Tubulis, Ouro and Arcellx acquisitions call. My name is Tamia, and I

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Gilead Sciences, Inc.

08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Gilead Sciences, Inc., Q2 2026 Earnings Call, Aug 04, 2026
08-04	Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue	DJ
08-04	Gilead Sciences Q2 Swings To Adjusted Loss, Revenue Rises	MT
08-04	(GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $0.30 - $0.65, vs. FactSet Est of $0.75 Loss	MT
08-04	Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B	MT
08-04	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26	MT
08-04	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26	MT
08-04	Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on August 7, 2025.	CI
08-04	Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.	CI
08-04	Gilead second-quarter sales rise 8%, beating Wall Street estimates	RE
08-04	Gilead Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI